Roland Walter, M.D., Ph.D., M.S.
Roland Walter, M.D., Ph.D., M.S.
Associate Professor
Clinical Research Division, Fred Hutch
Dr. Roland Walter is a hematologist who specializes in treating acute myeloid leukemia, or AML. His research seeks to develop new and improved antibody-based therapies in the laboratory that effectively kill AML cells, including treatments that eradicate the AML stem cells, and then to bring these therapies to patients.
Other Appointments & Affiliations
Associate Professor of Medicine, Division of Hematology
University of Washington School of Medicine
Adjunct Associate Professor, Department of Epidemiology
University of Washington School of Public Health
Adjunct Associate Professor, Department of Pathology
University of Washington School of Medicine
Education
M.S., Epidemiology, Clinical Research, University of Washington, 2011
Research Fellow, Clinical Research Division, 2002-08
Fellow, Division of Hematology, University of Washington, 2005-07
Ph.D., University of Washington, 2006
Resident, Internal Medicine, University Hospital, Zürich, Switzerland, 1999-02
Resident, Internal Medicine, Rätisches Kantons- und Regionalspital, Chur, Switzerland, 1997-99
M.D., Faculty of Medicine, University of Zürich, 1997
Medical School, University of Zürich, 1990-96
Research Interests
The preclinical and early clinical development and characterization of novel antigen-directed immunotherapies for AML
The conduct of trials testing novel treatments and innovative and innovative care approaches for AML patients
Approaches to develop and improve diagnostic and prognostic tools in AML
Active Clinical Trials
Gemtuzumab Ozogamicin With G-CSF, Cladribine, Cytarabine and Mitoxantrone in Treating Participants With Previously Untreated Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Study Number: 10000
Phase: I/II
CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients
Study Number: RG1005577
Phase: II
Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS
Study Number: 10050
Phase: I
A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Study Number: 9382
Phase: I
Study of APVO436 in Patients With AML or MDS
Study Number: RG1003382
Phase: I
Dr. Walter in the News
For the Media
The Media Relations team at Fred Hutch is available to assist members of the news media who would like to arrange interviews with faculty.
Email media@fredhutch.org or call 206.667.2210